Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 5/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.71 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.71 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25089914 | 0.86 | ADORA2B (0.76) | ADORA2BADORA2AKDM4ECYP1A2ADORA3 | |
| SCHEMBL25090466 | 0.86 | ADORA2B (0.78) | ADORA2BADORA2AKDM4ECYP1A2ADORA3 | |
| SCHEMBL25090609 | 0.85 | ADORA2B (0.73) | ADORA2BADORA2AKDM4ECYP1A2ADORA3 | |
| SCHEMBL516013 | 0.85 | ADORA2B (0.77) | ADORA2BADORA2AKDM4ECYP1A2ADORA3 | |
| SCHEMBL25090491 | 0.83 | ADORA2B (0.75) | ADORA2BADORA2AKDM4ECYP1A2ADORA3 | |
| SCHEMBL10723936 | 0.83 | ADORA2B (1.00) | ADORA2BADORA2AKDM4ECYP1A2ADORA3 | |
| SCHEMBL515588 | 0.83 | KDM4E (0.76) | ADORA2BADORA2AKDM4ECYP1A2ADORA3 | |
| SCHEMBL516029 | 0.83 | ADORA2B (0.75) | ADORA2BADORA2AKDM4ECYP1A2ADORA3 | |
| SCHEMBL7318169 | 0.83 | KDM4E (0.76) | ADORA2BADORA2AKDM4ECYP1A2ADORA3 | |
| SCHEMBL25090458 | 0.83 | ADORA2A (0.75) | ADORA2BADORA2AKDM4ECYP1A2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0165308-A4 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. | RICHARDSON VICKS INC (US) | 1986-05-16 | — | — | EP | claimed |
| US-4567183-A | SYNERGISTIC, POTENTIATION | ANALGESIC ASSOCIATES (US) | 1986-01-28 | — | — | US | claimed |
| EP-0165308-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. | RICHARDSON VICKS INC (US) | 1985-12-27 | — | — | EP | claimed |
| US-4558051-A | Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same | RICHARDSON-VICKS, INC. (US) | 1985-12-10 | — | — | US | claimed |
| WO-1985002540-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | RICHARDSON-VICKS, INC. (US) | 1985-06-20 | — | — | WO | claimed |
| US-20250386846-A1 | Food Compositions Including Aragonite | NANT HOLDINGS IP LLC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12419336-B2 | Beverage compositions including calcium supplied from aragonite and methods of making the same | NANT HOLDINGS IP, LLC (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250194654-A1 | Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same | NANT HOLDINGS IP, LLC | 2025-06-19 | — | — | US | disclosed |
| US-12310392-B2 | Beverage compositions including calcium supplied from aragonite and methods of making the same | NANT HOLDINGS IP, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240381918-A1 | Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same | NANT HOLDINGS IP, LLC | 2024-11-21 | — | — | US | disclosed |
| US-12089621-B2 | Beverage compositions including calcium supplied from aragonite and methods of making the same | NANT HOLDINGS IP, LLC (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230354865-A1 | Beverage Compositions Including Calcium Supplied From Aragonite And Methods Of Making The Same | NANT HOLDINGS IP, LLC | 2023-11-09 | — | — | US | disclosed |
| EP-0167566-A4 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. | SUNSHINE ABRAHAM (US) | 1987-06-29 | — | — | EP | disclosed |
| EP-0165308-A4 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. | RICHARDSON VICKS INC (US) | 1986-05-16 | — | — | EP | disclosed |
| US-4567183-A | SYNERGISTIC, POTENTIATION | ANALGESIC ASSOCIATES (US) | 1986-01-28 | — | — | US | disclosed |
| EP-0167566-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | SUNSHINE, Abraham (US) | 1986-01-15 | — | — | EP | disclosed |
| EP-0165308-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. | RICHARDSON VICKS INC (US) | 1985-12-27 | — | — | EP | disclosed |
| US-4558051-A | Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same | RICHARDSON-VICKS, INC. (US) | 1985-12-10 | — | — | US | disclosed |
| WO-1985002540-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | RICHARDSON-VICKS, INC. (US) | 1985-06-20 | — | — | WO | disclosed |
| WO-1985002542-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | SUNSHINE ABRAHAM | 1985-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250386846-A1 | Food Compositions Including Aragonite | PLCG2, PLCG1, PLCB3 | ADORA2B 1369/4885ADORA2A 2335/4885KDM4E 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.